GlassScriptPhysician profile
Phillip L Robinson
NPI 1912908633
$5,342.16
in general payments reported to CMS, 2019-2025
39 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $691 · 2021: $1,299 · 2022: $946 · 2023: $1,123 · 2024: $747 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.07 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,202.43 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $638.12 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $622.36 | 2020-2024 | Vraylar, Qulipta |
| Astellas Pharma US INC | $356.42 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $270.51 | 2020-2022 | |
| Allergan, INC. | $202.06 | 2019-2020 | |
| Myriad Women'S Health, INC. | $193.29 | 2023 | Myrisk |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.11 | 2020-2023 | Jardiance |
| Amgen INC. | $157.75 | 2020-2024 | Evenity, Prolia, Repatha |
| Esperion Therapeutics, INC. | $140.51 | 2020-2021 | |
| Daiichi Sankyo INC. | $122.06 | 2024-2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $121.24 | 2020-2024 | Farxiga |
| Glaxosmithkline, LLC. | $121.21 | 2020-2025 | Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $89.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $89.13 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phillip Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.